1 Study Coverage 1.1 Drugs for Central Nervous System Diseases Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Introduction 1.2 Global Drugs for Central Nervous System Diseases Outlook 2017 VS 2022 VS 2028 1.2.1 Global Drugs for Central Nervous System Diseases Market Size for the Year 2017-2028 1.2.2 Global Drugs for Central Nervous System Diseases Market Size for the Year 2017-2028 1.3 Drugs for Central Nervous System Diseases Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Drugs for Central Nervous System Diseases in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Drugs for Central Nervous System Diseases Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Drugs for Central Nervous System Diseases Market Dynamics 1.4.1 Drugs for Central Nervous System Diseases Industry Trends 1.4.2 Drugs for Central Nervous System Diseases Market Drivers 1.4.3 Drugs for Central Nervous System Diseases Market Challenges 1.4.4 Drugs for Central Nervous System Diseases Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Drugs for Central Nervous System Diseases by Type 2.1 Drugs for Central Nervous System Diseases Market Segment by Type 2.1.1 Antidepressants 2.1.2 Anxiolytics 2.1.3 Anti-manic 2.1.4 Other 2.2 Global Drugs for Central Nervous System Diseases Market Size by Type (2017, 2022 & 2028) 2.3 Global Drugs for Central Nervous System Diseases Market Size by Type (2017-2028) 2.4 United States Drugs for Central Nervous System Diseases Market Size by Type (2017, 2022 & 2028) 2.5 United States Drugs for Central Nervous System Diseases Market Size by Type (2017-2028) 3 Drugs for Central Nervous System Diseases by Application 3.1 Drugs for Central Nervous System Diseases Market Segment by Application 3.1.1 Hospital Pharmacies 3.1.2 Retail Pharmacies 3.1.3 Online Pharmacies 3.2 Global Drugs for Central Nervous System Diseases Market Size by Application (2017, 2022 & 2028) 3.3 Global Drugs for Central Nervous System Diseases Market Size by Application (2017-2028) 3.4 United States Drugs for Central Nervous System Diseases Market Size by Application (2017, 2022 & 2028) 3.5 United States Drugs for Central Nervous System Diseases Market Size by Application (2017-2028) 4 Global Drugs for Central Nervous System Diseases Competitor Landscape by Company 4.1 Global Drugs for Central Nervous System Diseases Market Size by Company 4.1.1 Top Global Drugs for Central Nervous System Diseases Companies Ranked by Revenue (2021) 4.1.2 Global Drugs for Central Nervous System Diseases Revenue by Player (2017-2022) 4.2 Global Drugs for Central Nervous System Diseases Concentration Ratio (CR) 4.2.1 Drugs for Central Nervous System Diseases Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Drugs for Central Nervous System Diseases in 2021 4.2.3 Global Drugs for Central Nervous System Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Drugs for Central Nervous System Diseases Headquarters, Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Type 4.3.1 Global Drugs for Central Nervous System Diseases Headquarters and Area Served 4.3.2 Global Drugs for Central Nervous System Diseases Companies Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Drugs for Central Nervous System Diseases Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Drugs for Central Nervous System Diseases Market Size by Company 4.5.1 Top Drugs for Central Nervous System Diseases Players in United States, Ranked by Revenue (2021) 4.5.2 United States Drugs for Central Nervous System Diseases Revenue by Players (2020, 2021 & 2022) 5 Global Drugs for Central Nervous System Diseases Market Size by Region 5.1 Global Drugs for Central Nervous System Diseases Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Drugs for Central Nervous System Diseases Market Size by Region (2017-2028) 5.2.1 Global Drugs for Central Nervous System Diseases Market Size by Region: 2017-2022 5.2.2 Global Drugs for Central Nervous System Diseases Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Drugs for Central Nervous System Diseases Market Size YoY Growth 2017-2028 6.1.2 North America Drugs for Central Nervous System Diseases Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Drugs for Central Nervous System Diseases Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Drugs for Central Nervous System Diseases Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Drugs for Central Nervous System Diseases Market Size YoY Growth 2017-2028 6.3.2 Europe Drugs for Central Nervous System Diseases Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Drugs for Central Nervous System Diseases Market Size YoY Growth 2017-2028 6.4.2 Latin America Drugs for Central Nervous System Diseases Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Drugs for Central Nervous System Diseases Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Drugs for Central Nervous System Diseases Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 U.A.E 7 Company Profiles 7.1 Alkermes 7.1.1 Alkermes Company Details 7.1.2 Alkermes Business Overview 7.1.3 Alkermes Drugs for Central Nervous System Diseases Introduction 7.1.4 Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) 7.1.5 Alkermes Recent Development 7.2 Astrazeneca 7.2.1 Astrazeneca Company Details 7.2.2 Astrazeneca Business Overview 7.2.3 Astrazeneca Drugs for Central Nervous System Diseases Introduction 7.2.4 Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) 7.2.5 Astrazeneca Recent Development 7.3 Biogen 7.3.1 Biogen Company Details 7.3.2 Biogen Business Overview 7.3.3 Biogen Drugs for Central Nervous System Diseases Introduction 7.3.4 Biogen Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) 7.3.5 Biogen Recent Development 7.4 Bristol Myers Squibb 7.4.1 Bristol Myers Squibb Company Details 7.4.2 Bristol Myers Squibb Business Overview 7.4.3 Bristol Myers Squibb Drugs for Central Nervous System Diseases Introduction 7.4.4 Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) 7.4.5 Bristol Myers Squibb Recent Development 7.5 Lilly 7.5.1 Lilly Company Details 7.5.2 Lilly Business Overview 7.5.3 Lilly Drugs for Central Nervous System Diseases Introduction 7.5.4 Lilly Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) 7.5.5 Lilly Recent Development 7.6 GSK 7.6.1 GSK Company Details 7.6.2 GSK Business Overview 7.6.3 GSK Drugs for Central Nervous System Diseases Introduction 7.6.4 GSK Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) 7.6.5 GSK Recent Development 7.7 Merck 7.7.1 Merck Company Details 7.7.2 Merck Business Overview 7.7.3 Merck Drugs for Central Nervous System Diseases Introduction 7.7.4 Merck Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) 7.7.5 Merck Recent Development 7.8 Sunovion Pharmaceuticals 7.8.1 Sunovion Pharmaceuticals Company Details 7.8.2 Sunovion Pharmaceuticals Business Overview 7.8.3 Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Introduction 7.8.4 Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) 7.8.5 Sunovion Pharmaceuticals Recent Development 7.9 Pfizer 7.9.1 Pfizer Company Details 7.9.2 Pfizer Business Overview 7.9.3 Pfizer Drugs for Central Nervous System Diseases Introduction 7.9.4 Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) 7.9.5 Pfizer Recent Development 7.10 Teva 7.10.1 Teva Company Details 7.10.2 Teva Business Overview 7.10.3 Teva Drugs for Central Nervous System Diseases Introduction 7.10.4 Teva Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) 7.10.5 Teva Recent Development 7.11 Norvatis 7.11.1 Norvatis Company Details 7.11.2 Norvatis Business Overview 7.11.3 Norvatis Drugs for Central Nervous System Diseases Introduction 7.11.4 Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) 7.11.5 Norvatis Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Drugs for Central Nervous System Diseases Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Drugs for Central Nervous System Diseases Market Trends Table 3. Drugs for Central Nervous System Diseases Market Drivers Table 4. Drugs for Central Nervous System Diseases Market Challenges Table 5. Drugs for Central Nervous System Diseases Market Restraints Table 6. Global Drugs for Central Nervous System Diseases Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Drugs for Central Nervous System Diseases Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Drugs for Central Nervous System Diseases Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Drugs for Central Nervous System Diseases Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Drugs for Central Nervous System Diseases Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Drugs for Central Nervous System Diseases Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Drugs for Central Nervous System Diseases Revenue Share by Player, 2017-2022 Table 13. Global Drugs for Central Nervous System Diseases Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Drugs for Central Nervous System Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Central Nervous System Diseases as of 2021) Table 15. Top Players of Drugs for Central Nervous System Diseases in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Drugs for Central Nervous System Diseases Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Drugs for Central Nervous System Diseases Players in United States Market, Ranking by Revenue (2021) Table 20. United States Drugs for Central Nervous System Diseases Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Drugs for Central Nervous System Diseases Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Drugs for Central Nervous System Diseases Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Drugs for Central Nervous System Diseases Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Drugs for Central Nervous System Diseases Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Drugs for Central Nervous System Diseases Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Drugs for Central Nervous System Diseases Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Drugs for Central Nervous System Diseases Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Drugs for Central Nervous System Diseases Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Drugs for Central Nervous System Diseases Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Alkermes Company Details Table 31. Alkermes Business Overview Table 32. Alkermes Drugs for Central Nervous System Diseases Product Table 33. Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Table 34. Alkermes Recent Development Table 35. Astrazeneca Company Details Table 36. Astrazeneca Business Overview Table 37. Astrazeneca Drugs for Central Nervous System Diseases Product Table 38. Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Table 39. Astrazeneca Recent Development Table 40. Biogen Company Details Table 41. Biogen Business Overview Table 42. Biogen Drugs for Central Nervous System Diseases Product Table 43. Biogen Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Table 44. Biogen Recent Development Table 45. Bristol Myers Squibb Company Details Table 46. Bristol Myers Squibb Business Overview Table 47. Bristol Myers Squibb Drugs for Central Nervous System Diseases Product Table 48. Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Table 49. Bristol Myers Squibb Recent Development Table 50. Lilly Company Details Table 51. Lilly Business Overview Table 52. Lilly Drugs for Central Nervous System Diseases Product Table 53. Lilly Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Table 54. Lilly Recent Development Table 55. GSK Company Details Table 56. GSK Business Overview Table 57. GSK Drugs for Central Nervous System Diseases Product Table 58. GSK Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Table 59. GSK Recent Development Table 60. Merck Company Details Table 61. Merck Business Overview Table 62. Merck Drugs for Central Nervous System Diseases Product Table 63. Merck Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Table 64. Merck Recent Development Table 65. Sunovion Pharmaceuticals Company Details Table 66. Sunovion Pharmaceuticals Business Overview Table 67. Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Product Table 68. Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Table 69. Sunovion Pharmaceuticals Recent Development Table 70. Pfizer Company Details Table 71. Pfizer Business Overview Table 72. Pfizer Drugs for Central Nervous System Diseases Product Table 73. Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Table 74. Pfizer Recent Development Table 75. Teva Company Details Table 76. Teva Business Overview Table 77. Teva Drugs for Central Nervous System Diseases Product Table 78. Teva Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Table 79. Teva Recent Development Table 80. Norvatis Company Details Table 81. Norvatis Business Overview Table 82. Norvatis Drugs for Central Nervous System Diseases Product Table 83. Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2017-2022) & (US$ Million) Table 84. Norvatis Recent Development Table 85. Research Programs/Design for This Report Table 86. Key Data Information from Secondary Sources Table 87. Key Data Information from Primary Sources List of Figures Figure 1. Drugs for Central Nervous System Diseases Product Picture Figure 2. Global Drugs for Central Nervous System Diseases Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Drugs for Central Nervous System Diseases Market Size 2017-2028 (US$ Million) Figure 4. United States Drugs for Central Nervous System Diseases Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Drugs for Central Nervous System Diseases Market Size 2017-2028 (US$ Million) Figure 6. United States Drugs for Central Nervous System Diseases Market Share in Global 2017-2028 Figure 7. Drugs for Central Nervous System Diseases Report Years Considered Figure 8. Product Picture of Antidepressants Figure 9. Product Picture of Anxiolytics Figure 10. Product Picture of Anti-manic Figure 11. Product Picture of Other Figure 12. Global Drugs for Central Nervous System Diseases Market Share by Type in 2022 & 2028 Figure 13. Global Drugs for Central Nervous System Diseases Market Size by Type (2017-2028) & (US$ Million) Figure 14. Global Drugs for Central Nervous System Diseases Market Share by Type (2017-2028) Figure 15. United States Drugs for Central Nervous System Diseases Market Share by Type in 2022 & 2028 Figure 16. United States Drugs for Central Nervous System Diseases Market Size by Type (2017-2028) & (US$ Million) Figure 17. United States Drugs for Central Nervous System Diseases Market Share by Type (2017-2028) Figure 18. Product Picture of Hospital Pharmacies Figure 19. Product Picture of Retail Pharmacies Figure 20. Product Picture of Online Pharmacies Figure 21. Global Drugs for Central Nervous System Diseases Market Share by Application in 2022 & 2028 Figure 22. Global Drugs for Central Nervous System Diseases Market Size by Application (2017-2028) & (US$ Million) Figure 23. Global Drugs for Central Nervous System Diseases Market Share by Application (2017-2028) Figure 24. United States Drugs for Central Nervous System Diseases Market Share by Application in 2022 & 2028 Figure 25. United States Drugs for Central Nervous System Diseases Market Size by Application (2017-2028) & (US$ Million) Figure 26. United States Drugs for Central Nervous System Diseases Market Share by Application (2017-2028) Figure 27. North America Drugs for Central Nervous System Diseases Market Size Growth Rate 2017-2028 (US$ Million) Figure 28. U.S. Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 29. Canada Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 30. Europe Drugs for Central Nervous System Diseases Market Size Growth Rate 2017-2028 (US$ Million) Figure 31. Germany Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 32. France Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. U.K. Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. Italy Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Russia Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 36. Asia-Pacific Drugs for Central Nervous System Diseases Market Size Growth Rate 2017-2028 (US$ Million) Figure 37. China Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. Japan Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. South Korea Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. India Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. Australia Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Taiwan Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Indonesia Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Thailand Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Malaysia Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 46. Philippines Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 47. Latin America Drugs for Central Nervous System Diseases Market Size Growth Rate 2017-2028 (US$ Million) Figure 48. Mexico Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 49. Brazil Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 50. Argentina Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 51. Middle East & Africa Drugs for Central Nervous System Diseases Market Size Growth Rate 2017-2028 (US$ Million) Figure 52. Turkey Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 53. Saudi Arabia Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 54. U.A.E Drugs for Central Nervous System Diseases Market Size Growth Rate (2017-2028) & (US$ Million) Figure 55. Alkermes Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2017-2022) Figure 56. Astrazeneca Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2017-2022) Figure 57. Biogen Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2017-2022) Figure 58. Bristol Myers Squibb Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2017-2022) Figure 59. Lilly Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2017-2022) Figure 60. GSK Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2017-2022) Figure 61. Merck Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2017-2022) Figure 62. Sunovion Pharmaceuticals Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2017-2022) Figure 63. Pfizer Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2017-2022) Figure 64. Teva Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2017-2022) Figure 65. Norvatis Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2017-2022) Figure 66. Bottom-up and Top-down Approaches for This Report Figure 67. Data Triangulation Figure 68. Key Executives Interviewed

Alkermes Astrazeneca Biogen Bristol Myers Squibb Lilly GSK Merck Sunovion Pharmaceuticals Pfizer Teva Norvatis